Throwback to SABCS 2024: Dr. Mafalda Oliveira on HER3-DXd in High-Risk HR+/HER2- Early Breast Cancer

Throwback to SABCS 2024: Dr. Mafalda Oliveira on HER3-DXd in High-Risk HR+/HER2- Early Breast Cancer

Throwback to SABCS 2024, where Dr. Mafalda Oliveira presented findings from the SOLTI VALENTINE phase II trial, evaluating HER3-DXd alone or in combination with letrozole as a neoadjuvant treatment for high-risk HR+/HER2-negative early breast cancer (EBC). The study explored whether HER3-DXd could serve as an effective and tolerable alternative to standard multi-agent chemotherapy.
Annual Review | Dr. Jun Guo: Advances in Systemic Therapy for Melanoma in 2024

Annual Review | Dr. Jun Guo: Advances in Systemic Therapy for Melanoma in 2024

Malignant melanocytes can appear in various tissues throughout the body, most commonly in the skin and mucous membranes, and are highly aggressive. With continuous advancements in targeted therapy, immunotherapy, and biological therapy, even advanced melanoma can, in many cases, be managed as a chronic disease. Looking back at 2024, what were the key research developments and treatment strategies in systemic therapy for melanoma? Oncology Frontier invited Dr. Jun Guo, Vice President of the Chinese Society of Clinical Oncology (CSCO) and professor at Peking University Cancer Hospital, to provide an expert review and summary. From Professor Guo’s annual analysis, it is evident that numerous novel treatment strategies have already begun or are poised to impact clinical practice, including some pioneering approaches originating from China.
ASCO GI 2025 | Dr. Rongbo Lin: SYLT-026 Study Marks a Breakthrough in Immunotherapy for MSS-Type Colorectal Cancer

ASCO GI 2025 | Dr. Rongbo Lin: SYLT-026 Study Marks a Breakthrough in Immunotherapy for MSS-Type Colorectal Cancer

Microsatellite stable (MSS) and mismatch repair-proficient (pMMR) metastatic colorectal cancer (mCRC) has shown minimal response to immune checkpoint inhibitors as monotherapy, making combination immunotherapy a key strategy to address this clinical challenge. At the 2025 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI 2025), a multicenter phase II study led by Dr. Rongbo Lin from Fujian Cancer Hospital was selected for the poster abstract session (Abstract #198). This study evaluates the preliminary efficacy and safety of FOLFOXIRI combined with bevacizumab and cadonilimab in pMMR/MSS mCRC patients.  During the conference, a reporter from Oncology Frontier conducted an in-depth interview with Dr. Rongbo Lin to discuss the study findings.
ASCO GI 2025 | Dr. Lin Shen & Dr. Zhi Peng: PD-L1/TGF-βRII Bispecific Antibody SHR-1701 Improves Efficacy and Protects Bone Marrow in First-Line Treatment of G/GEJA

ASCO GI 2025 | Dr. Lin Shen & Dr. Zhi Peng: PD-L1/TGF-βRII Bispecific Antibody SHR-1701 Improves Efficacy and Protects Bone Marrow in First-Line Treatment of G/GEJA

From January 23 to 25, 2025, the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) was held in San Francisco, showcasing significant advancements in gastrointestinal cancer treatment. The Peking University Cancer Hospital presented a series of cutting-edge findings, contributing to global progress in digestive tract oncology. On the first day of the conference, Dr. Zhi Peng from Peking University Cancer Hospital delivered an oral presentation on the latest findings from a Phase III clinical study evaluating the domestically developed PD-L1/TGF-βRII bispecific fusion protein SHR-1701 in first-line treatment for HER2-negative gastric and gastroesophageal junction adenocarcinoma (G/GEJA). Building upon the efficacy improvements previously reported at the European Society for Medical Oncology (ESMO) Congress, the latest data presented at ASCO GI suggests that SHR-1701 combined with chemotherapy may mitigate chemotherapy-induced bone marrow suppression, offering a more effective and safer treatment option for G/GEJA.